Welcome to the e-CCO Library!

P690: Prolonged benefit of filgotinib in patients with Ulcerative Colitis in SELECTION
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Laharie, D.(1)*;Sturm, A.(2);Kobayashi, T.(3);Matsumoto, T.(4);Oortwijn, A.(5);Jamoul , C.(6);Faes, M.(6);de Haas, A.(7);Vermeire , S.(8);
Created: Friday, 14 July 2023, 11:12 AM
P690: Rates of IBD in New Zealand Māori population at Lakes District Health Board: low but increasing
Year: 2022
Source: ECCO'22
Authors: Qiu, M.(1);Patel, R.N.(2);Gearry, R.B.(3,4);
Created: Friday, 11 February 2022, 3:56 PM
P691 Corticosteroids usage in patients with inflammatory bowel disease: Results of a multi-national audit in Asia
Year: 2020
Source:

ECCO'20 Vienna

Authors:

D.H. Kim1, D.I. Park2, T. Kobayashi3, V. Ahuja4, B.I. Jang5, Q. Cao6, Y.J. Lee7, Z. Ran8, Clinical Research Committee of Asian Organization for Crohn’s and Colitis (AOCC)

Created: Thursday, 30 January 2020, 10:12 AM
P691: Cx601, a novel stem cell therapy for complex perianal fistulas in Crohn’s disease has rapid onset of clinical remission and low relapse rate by week 52
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. García-Olmo1, J. Panés2*, N. Brayshaw3, M.P. Richard4, C. Agboton5

Created: Thursday, 21 February 2019, 9:14 AM
P691: Disparate care: rates of treat to target among patients with inflammatory bowel disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Haydek, J.(1);Oonk, A.(1);Cheng, D.(1);Ahmed, W.(1);Click, B.(1);Fennimore, B.(1);Gerich, M.(1);Hou, J.(2);Scott, F.(1)*;
Created: Friday, 14 July 2023, 11:12 AM
P691: Influence of ethnicity on the phenotype and clinical outcomes in Inflammatory Bowel Disease; comparison of a South American with a North American population.
Year: 2022
Source: ECCO'22
Authors: Pérez, T.(1);Pizarro, B.(2); Ascui, G.(3);Tobar, F.(4);Cerda-Villablanca, M.(5);Alvares, D.(6);Orellana, M.(7);De la Vega, A.(8);Canistra, M.(9);Cornejo, B.(9);Baez, P.(10);Silva, V.(2);Arriagada, E.(8);Estela, R.(2);Hernandez-Rocha, C.(11);Alvarez-Lobos, M.(12);Rivera-Nieves, J.(13);
Created: Friday, 11 February 2022, 3:56 PM
P691: Trends in diagnostic prevalence and treatment patterns of adult ulcerative colitis patients in the USA, 2007–2017
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Hunter*1, A. Naegeli1, Y. Dong1, C. Choong1, D. Stefani-Hunyady1

Created: Friday, 22 February 2019, 9:41 AM
P691: UV exposure and skin type are more important than thiopurine exposure for non-melanoma skin cancer risk in IBD
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Wu Y.*1, Ghaly S.1, Kerr S.2, Krishnaprasad K.3, Prosser R.4, Jackson B.5, Hanigan K.3, Martins D.3, Mountifield R.4, Whiteman D.6, Bampton P.4, Gearry R.5, Radford-Smith G.3, Lawrance I.C.7,8

Created: Wednesday, 20 February 2019, 10:36 AM
P692 Exploring relationships between microbiome, faecal calprotectin and healthy eating index in patients with ulcerative colitis: Interim analyses of a randomised controlled trial
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Raman1, L. Taylor1, A. Schick2, C. Ohland2, K. McCoy2, S. Kaur1, R. Panaccione1, R. Reimer3

Created: Thursday, 30 January 2020, 10:12 AM
P692: Clinical, therapeutic and evolutionary profile of fistulizing ano-perineal lesions in Crohn's disease
Year: 2022
Source: ECCO'22
Authors: Hassine, H.(1);KAHLAOUI, F.(1);Mtir, M.(1);Cherif, D.(1);Tlili, R.(1);Kchir, H.(1);Maamouri, N.(1);
Created: Friday, 11 February 2022, 3:56 PM
P692: Efficacy and safety of early biologic treatment of Crohn’s disease in adult and paediatric patients: A systematic review
Year: 2018
Source: ECCO '18 Vienna
Authors:

J.-F. Colombel1*, R. Ungaro1, S. Aggarwal2, O. Topaloglu2, M. Skup3, W.-J. Lee3

Created: Thursday, 21 February 2019, 9:14 AM
P692: Inflammatory bowel diseases in Faroese-born Danish residents and their offspring. Further evidence of the dominant role of environmental factors in IBD development
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Hammer T.*1,2, Lophaven S.N.1, Rubek Nielsen K.3,4, von Euler-Chelpin M.C.1, Weihe P.2, Munkholm P.5, Burisch J.5, Lynge E.1

Created: Wednesday, 20 February 2019, 10:36 AM
P692: Positive histological margins is a risk factor of recurrence after ileocaecal resection in Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Riault*1, M. Diouf2, D. Chatelain2, J. p. Le Mouel1, J. Loreau1, J. Turpin1, C. Yzet1, F. Brazier1, C. Sabbagh2, J. l. Dupas1, E. Nguyen-Khac1, M. Fumery1

Created: Friday, 22 February 2019, 9:41 AM
P693 Development and evaluation of i-TRACKER infliximab and i-TRACKER anti-Infliximab kits: fast and innovative chemiluminescent assays for the monitoring of patients treated with infliximab
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G. Noguier1, C. Montaillier1, S. Daviere2, L. Colombeau1, E. Parussini1

Created: Thursday, 30 January 2020, 10:12 AM
P693: Italian real-life study evaluating the long-term effectiveness of vedolizumab for the treatment of Inflammatory Bowel Disease- An IG-IBD study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Pugliese, D.(1);Privitera, G.(2)*;Armuzzi, A.(3);
Created: Friday, 14 July 2023, 11:12 AM
P693: Patients with inflammatory bowel disease who are on immunosuppressive therapy perform regular gynecologic screening for uterine cervical cancer?
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Vázquez-Morόn J.M., Cabello Fernández A., Pallarés-Manrique H., Ramos-Lora M.

Created: Wednesday, 20 February 2019, 10:36 AM
P693: Should extraintestinal manifestations (EIMs) be part of disease activity assessment in ulcerative colitis?
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Walsh1, A. Kormilitzin2, C. Hinds3, V. Sexton4, J. Wilson1, O. Brain1*, S. Keshav1, H. Uhlig1, J. Geddes4, G. Goodwin4, M. Peters5, G. Collins6, S. Travis1

Created: Thursday, 21 February 2019, 9:14 AM
P693: Vedolizumab treatment for pouch inflammation
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Hirsch*1, H. Tulchinsky2, N. Maharshak1

Created: Friday, 22 February 2019, 9:41 AM
P693: Willingness and hesitancy to the telemedicine in patients with inflammatory bowel disease during COVID-19 outbreak. Preliminary results of a survey in an Italian IBD Center
Year: 2022
Source: ECCO'22
Authors: Bossa, F.(1);Guerra, M.(1);Carparelli, S.(1);Antonella, M.(1);Terracciano, F.(1);Costantino, A.(2);Caprioli, F.(2);Valvano, M.R.(1);Martino, G.(1);Nardella, M.(1);Perri, F.(1);
Created: Friday, 11 February 2022, 3:56 PM
P694 Validation of two commercial assays for therapeutic drug monitoring of adalimumab biosimilars
Year: 2020
Source:

ECCO'20 Vienna

Authors:

R. Berghmans1, J. Naudts2, B. Ferkinghoff3, H. Gören3, M.L. Henke3, A. Lennerz4, T. Van Stappen4

Created: Thursday, 30 January 2020, 10:12 AM